Drug Profile
FK 779
Alternative Names: FK-779; HMR 1279; MNA 279; X 910279Latest Information Update: 18 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Astellas Pharma; sanofi-aventis
- Class Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Multiple sclerosis; Transplant rejection
Most Recent Events
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 28 Jul 2003 Preclinical trials in Transplant rejection in North America (PO)